ACT Brief: Targeted Trial Growth, Site Startup Strains, and Leadership Shake-Up at FDA

In today’s ACT Brief, we look at new insights on strategy-driven clinical development, fresh survey data revealing persistent site startup delays, and major leadership turnover inside FDA’s drug division.